Epistaxis Clinical Trial
Official title:
An Open-label, Non-randomized Study of the Efficacy of Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.
Based on frequency and nose bleed duration, a non-randomized, single arm, open label study of 30 hereditary hemorrhagic telangiectasia patients will be treated with very low dose Pazopanib [25mg-similar] for between 16 and 24 weeks.. The primary endpoint is a reduction in bleeding duration of 50% or more, along with multiple secondary related endpoints, including bleed frequency, blood counts and quality of life; as compared to 6-12 weeks of baseline characteristics. If after the first 8 weeks of therapy benefit is suboptimal, dose advance to 50mg-similar daily can be considered. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05334017 -
Xylometazoline and Cocaine for Nasal Vasoconstriction
|
Phase 4 | |
| Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
| Recruiting |
NCT01886768 -
Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy
|
N/A | |
| Recruiting |
NCT00390663 -
A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children
|
Phase 4 | |
| Suspended |
NCT04054687 -
Intranasal TXA for Anterior Epistaxis in the Emergency Department
|
Phase 2 | |
| Completed |
NCT02285634 -
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
|
N/A | |
| Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
| Completed |
NCT00793117 -
The Effect of Packing in Post Operative Management of FESS
|
Phase 4 | |
| Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
| Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05281952 -
Medico-economic Evaluation of Management Strategies for Severe Epistaxis
|
N/A | |
| Completed |
NCT03360045 -
Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis
|
Phase 4 | |
| Completed |
NCT04279288 -
The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures
|
N/A | |
| Completed |
NCT03912051 -
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
|
N/A | |
| Not yet recruiting |
NCT02677467 -
Correlation Between Epistaxis and Cardiovascular Disease
|
N/A | |
| Completed |
NCT01314274 -
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Terminated |
NCT01051427 -
Control of Epistaxis With Surgiflo
|
N/A | |
| Completed |
NCT00863356 -
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
|
N/A | |
| Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
| Not yet recruiting |
NCT05343650 -
NOVAPAK Nasal Packing in Shellfish Allergic Patients
|
Phase 4 |